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Abstract
Background: Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are sight-threatening
complications of diabetes mellitus and leading causes of adult-onset blindness worldwide. Genetic risk factors for
diabetic retinopathy (DR) have been described previously, but have been difficult to replicate between studies,
which have often used composite phenotypes and been conducted in different populations. This study aims to
identify genetic risk factors for DME and PDR as separate complications in Australians of European descent with
type 2 diabetes.
Methods: Caucasian Australians with type 2 diabetes were evaluated in a genome-wide association study (GWAS)
to compare 270 DME cases and 176 PDR cases with 435 non-retinopathy controls. All participants were genotyped
by SNP array and after data cleaning, cases were compared to controls using logistic regression adjusting for
relevant covariates.
Results: The top ranked SNP for DME was rs1990145 (p = 4.10 × 10− 6, OR = 2.02 95%CI [1.50, 2.72]) on chromosome
2. The top-ranked SNP for PDR was rs918519 (p = 3.87 × 10− 6, OR = 0.35 95%CI [0.22, 0.54]) on chromosome 5. A
trend towards association was also detected at two SNPs reported in the only other reported GWAS of DR in Caucasians;
rs12267418 near MALRD1 (p= 0.008) in the DME cohort and rs16999051 in the diabetes gene PCSK2 (p = 0.007) in the
PDR cohort.
Conclusion: This study has identified loci of interest for DME and PDR, two common ocular complications of diabetes.
These findings require replication in other Caucasian cohorts with type 2 diabetes and larger cohorts will be required to
identify genetic loci with statistical confidence. There is considerable overlap in the patient cohorts with each retinopathy
subtype, complicating the search for genes that contribute to PDR and DME biology.
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Background
Diabetic retinopathy (DR) is a common and potentially
blinding complication of both type 1 and type 2 diabetes
mellitus. The disease affects multiple vascular and neural
cell types of the retina and is the leading cause of new
cases of blindness in working aged adults [1]. The early
non-proliferative DR (NPDR) stages are characterized by
retinal microaneurysms, lipid and protein deposits and
cotton wool spots due to damage to retinal vasculature.
The later stage, characterised by neovascularisation of
the retina is called proliferative DR (PDR). Patients may
also develop diabetic macular edema (DME) character-
ized by build-up of fluid in and beneath the macula, af-
fecting detailed central vision, with or without PDR or
NPDR. The prevalence of any retinopathy among pa-
tients with diabetes is 40.3%, with a prevalence of 8.2%
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for sight threatening DR, classified as severe NPDR,
PDR or DME [2].
Longer duration of diabetes, poor glycemic control,
hypertension, dyslipidemia, central obesity, smoking and
high blood pressure are well-documented risk factors for
ocular diabetic complications [3, 4]. Genetic factors,
however, also play an important role. Family studies have
shown that siblings have a greater chance of developing
DR, irrespective of other risk factors and the heritable
component of DR has been calculated in the range of
25–50% [5, 6]. Candidate gene studies have identified
numerous genetic variants that may contribute to risk,
but have often been inconsistent [7, 8]. Genome-wide
association studies (GWAS) are an efficient method to
search for genetic variants associated with complex dis-
eases, including DR.
Six GWAS for DR related phenotypes have been re-
ported to date. The first was conducted in Mexican-
Americans with type 2 diabetes with severe NDPR or
PDR [9]. Subsequent studies in Taiwanese [10] and Japa-
nese [11] participants used a similar disease definition
whereas a study in Chinese patients was limited to PDR
[12]. The most recent study in type 2 diabetes used a
composite definition of blinding DR which included pa-
tients with severe NPDR, PDR or DME [13] and was
conducted in Caucasian participants for the first time.
Only one GWAS for DR has been reported in patients
with type 1 diabetes [14]. This study was also conducted
in a Caucasian cohort and included patients with DME
and PDR as cases. Although many loci have been sug-
gested through these studies, there has been limited suc-
cess in replicating findings between studies, partly due
to small study sizes increasing the likelihood of false
positive findings and partly due to different ethnic
groups and disease definitions under investigation.
Previous GWAS in Caucasian cohorts have, to date,
only considered composite phenotypes. This may limit
the results by creating heterogeneous groups with differ-
ent underlying genetic risk factors. Therefore, we under-
took a re-analysis of our previously reported GWAS in
Australians with type 2 diabetes [13] stratified by pa-
tients with PDR and those with DME, separately. We
then compared our findings to those reported in the
only other published DR GWAS of Caucasian patients,
reported by Grassi et al. [14].
Methods
Recruitment of participants and clinical data collection
In South Australia, ethics approval was obtained from
the Southern Adelaide Health Service Flinders Univer-
sity Clinical Research Ethics Committee (Flinders
Medical Centre and Repatriation General Hospital), and
the Human Research Ethics Committees (HREC) of the
Royal Adelaide Hospital and Queen Elizabeth Hospital.
In New South Wales and Victoria, the HREC of South-
eastern Sydney and Illawara Northern Hospital Network
(Sydney Eye Hospital), and the HREC of Melbourne
Health (Royal Melbourne Hospital) approved this study.
The ACT Health HREC approved this study in the
Australian Capital Territory. This retrospective, cross
sectional study adhered to the tenets of the Declaration
of Helsinki. Written informed consent was obtained
from all study participants, who have been previously
described [13, 15]. Briefly, patients with medically
treated type 2 diabetes for at least 5-years were recruited
and underwent a thorough ophthalmological examin-
ation. DR and DME was graded on clinical examination
according to recognised severity scales based on ETDRS
criteria [16]. Participants completed a detailed question-
naire and concurrent clinical measurements for blood
pressure, renal function and HbA1c were obtained. Pa-
tients were classified as controls if they had no sign of
DR or DME. Cases were defined as those with PDR and
those with DME present in their worst affected eye, to
be analyzed as two separate case cohorts. Patients with
mild, moderate or severe NPDR were excluded from the
current analysis although some patients with DME had
NPDR concurrently. Those with both DME and PDR
were included in both case cohorts.
SNP genotyping and data analysis
Genotyping of single nucleotide polymorphisms (SNPs)
across the whole genome have been previously described
[13]. Briefly, genomic DNA extracted from whole blood
from each individual was genotyped on the OmniEx-
press SNP array (Illumina). Standard quality control fil-
ters were applied to the genotype data and 617,130 SNPs
were included in the subsequent analyses. Principal
components analysis was conducted using Eigenstrat
[17] and individuals falling greater than six standard de-
viations from the mean of each vector were removed.
Q-Q and Manhattan plots were generated using the
qqman package [18] in R (https://www.r-project.org/).
Demographic and clinical characteristics were com-
pared using t-tests for continuous traits and chi-squared
tests for dichotomous traits. Association of each SNP
passing quality control with each DR phenotype (DME
and PDR) was assessed using logistic regression adjusted
for the covariates age, diabetes duration, sex, hyperten-
sion, nephropathy, HbA1c and the first three principal
components, using PLINK [19]. P-values < 5 × 10− 8 were
deemed to be significant at a genome-wide level. SNPs
for comparison with other Caucasian GWAS were
chosen from Grassi et al., 2011 [14]. For reported SNPs
that were not directly genotyped in the current study, a
proxy SNP with r2 > 0.8 with the reported SNP in
HapMap was chosen as described previously [13].
Where no such SNP was available, the SNP with the
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smallest p-value within 50 kb from the reported SNP
was selected. When assessing the eight previously
reported loci a p-value < 0.0063 was considered signifi-
cant under a Bonferroni correction for eight independ-
ent tests.
Results
The DR phenotypes of all participants are shown in
Table 1. The PDR cohort consisted of 176 cases (with or
without DME) while the DME cohort had 270 cases
(with or without PDR). 93 participants had both DME
and PDR and were common to both case cohorts. The
controls with no PDR or DME were also common to
both groups.
The demographics and clinical characteristics of both
cases compared to controls are shown in Table 2. Well
known DR risk factors including; duration of diabetes,
hypertension, nephropathy and HbA1c were significantly
different between the control and case groups in both
cohorts. Age and sex were associated with PDR with
cases being younger and more likely to be male than
controls, but this association was not seen with DME.
The effects of population stratification were assessed
through visualisation of the Q-Q plots (Fig. 1a and b)
and lambda values (λ = 0.981, λ1000 = 0.943 for DME; λ =
1.001, λ1000 = 1.004 for PDR) and determined to be neg-
ligible following adjustment for the first three principal
components. The Manhattan plots (Fig. 1c and d) show
the association results for both DME and PDR analyses.
Association results for DME (Additional file 1) and
PDR (Additional file 2) showed 7 variants reaching sug-
gestive significance (Table 3). None of the SNPs reached
genome-wide significance (p < 5 × 10− 8). In the DME
analysis, only two SNPs displayed p-values < 1.0 × 10− 5.
The highest ranked SNP was rs1990145 (p = 4.10 × 10− 6,
OR = 2.02 95%CI [1.50, 2.72]) located in an intron of the
MRPL19 gene on chromosome 2. The second SNP,
rs4771506 (p = 6.94 × 10− 6, OR = 1.97 [1.46, 2.64]), is on
chromosome 13 near the LINC00343 gene. In the PDR
analysis the top ranked SNP, rs918519 (p = 3.87 × 10− 6,
OR = 0.35 [0.22, 0.54]) and the fifth ranked SNP,
rs918520 (p = 6.66 × 10− 6, OR = 0.34 [0.21, 0.54]) on
chromosome 5, are near the long non-coding RNA gene
LOC285626 while the closest protein coding gene is
IL12B. Three SNPs near the NRXN3 gene on chromo-
some 14 are also suggestive of association with PDR.
We compared our results to the only other published
GWAS of DR in Caucasians. SNPs associated with sight-
threatening DR in the type 1 diabetes cohorts reported
by Grassi et al. (2011) [14] were evaluated in the DME
and PDR datasets. Although none of the SNPs reached
formal statistical significance for the eight loci tested at
p < 0.006, two SNPs showed a strong trend towards as-
sociation with p ≤ 0.008 (Table 4). The chromosome 10
SNP rs12267418 near MALRD1, was associated with
DME, but clearly not with PDR. Further, the chromo-
some 20 proxy SNP rs16999051 within PCSK2 was asso-
ciated with PDR (p = 0.007) and was also nominally
associated with DME (p = 0.038). Both these associations
are in the same direction as in the original report.
Discussion
These GWAS analysed DME and PDR as separate phe-
notypes of the previously reported sight-threatening DR
phenotype of Burdon et al. (2015) [13]. This is the first
reported GWAS of DME in any ethnic group. Although
no SNPs reached genome wide statistical significance,
several suggestive loci have been identified for future in-
vestigation in other cohorts with DME phenotyping. The
top ranked SNP for DME, rs1990145 is within the sec-
ond intron of the mitochondrial ribosomal protein L19
(MRPL19). Although there have been no reports on this
gene’s involvement with diabetic retinopathy, it is
expressed in the retina (The Ocular Tissue Database
[20]). Evidence suggests a key role for mitochondrial
dysfunction in age-related macular degeneration [21].
Polymorphisms in this gene may result in mitochondrial
dysfunction and associated eye pathology, with under-
lying subclinical phenotypes unmasked by conditions of
stress such as diabetes and hyperglycaemia. At least
three other MRP genes; MRPL9, MRPL23, and MRPL39
map to genomic regions associated with retinitis
Table 1 Retinopathy grading of study cohorts. All participants
had type 2 diabetes
Retinopathy grading N
No retinopathy (controls) 435
DME only 177
PDR only 83
DME and PDR 93
DME diabetic macular edema, PDR proliferative diabetic retinopathy, N number
of participants
Table 2 Demographics and clinical characteristics of DME and
PDR cases and comparison to controls
Controls DME Cases P PDR Cases P
Number 435 270 176
Age (yrs) 66.5 ± 12.6 65.9 ± 10.6 0.491 62.7 ± 10.6 < 0.001
Duration (yrs) 12.6 ± 7.1 19.2 ± 8.8 < 0.001 19.1 ± 8.9 < 0.001
Female 48.5% 43.0% 0.151 35.2% 0.003
Hypertension 76.8% 88.1% < 0.001 87.5% 0.003
Nephropathy 12.2% 24.4% < 0.001 29.5% < 0.001
HbA1c (%) 7.5 ± 1.5 8.8 ± 1.8 < 0.001 8.9 ± 1.9 < 0.001
For continuous variables, values are given as the mean ± standard deviation.
For dichotomous variables, values are given as a %. HbA1c is a % of total
haemoglobin. Duration = known duration of type 2 diabetes in years
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pigmentosa [22] indicating the importance of this path-
way in retinal pathology. The second ranked DME SNP,
rs4771506, is approximately 80 kb from the long inter-
genic non-protein coding RNA 343 (LINC00343). The
nearest protein coding gene is DAOA, D-amino acid oxi-
dase activator, approximately 350 kb upstream from the
SNP. It is difficult to hypothesise a functional role for
this SNP or the nearest genes in DME and replication of
these findings is clearly required.
This study is the first GWAS of PDR in Caucasians.
We identified suggestive association of two SNPs within
LOC285626 and three SNPs within NRXN3 with PDR.
The presence of multiple SNPs at each locus with simi-
lar statistical evidence provides confidence in the find-
ings, although, as for DME, replication and larger
studies are clearly needed. LOC285626 is approximately
35 kb upstream of the two chromosome 5 SNPs and en-
codes an uncharacterised, long non-coding RNA. The
Fig. 1 Q-Q plots and Manhattan plots for DME and PDR GWAS. Q-Q plots for (a) Diabetic Macular Edema and (b) Proliferative Diabetic Retinopathy
GWAS. Manhattan plots for (c) Diabetic Macular Edema and (d) Proliferative Diabetic Retinopathy GWAS. The blue horizontal line represents suggestive
association at p = 1.0 × 10− 5
Table 3 Top ranked SNPs associated with DME and PDR. SNPs with p < 1.0 × 10− 5 for each phenotype are shown
Phenotype Chr SNP Position in hg 38 (bp) Minor allele MAF cases MAF controls OR (95% CI) P Nearest gene
DME 2 rs1990145 75,650,524 A 0.364 0.268 2.02 (1.50, 2.72) 4.10 × 10− 6 MRPL19
13 rs4771506 105,843,651 C 0.325 0.263 1.97 (1.46, 2.64) 6.94 × 10− 6 LINC00343
PDR 5 rs918519 159,399,349 T 0.163 0.231 0.35 (0.22, 0.54) 3.87 × 10− 6 LOC285626
14 rs1158314 79,961,389 G 0.515 0.400 2.16 (1.56, 3.00) 4.01 × 10− 6 NRXN3
14 rs8004963 79,958,817 C 0.515 0.400 2.16 (1.56, 3.00) 4.01 × 10− 6 NRXN3
14 rs11159428 79,950,890 T 0.512 0.399 2.13 (1.54, 2.95) 5.63 × 10−6 NRXN3
5 rs918520 159,399,302 C 0.131 0.211 0.34 (0.21, 0.54) 6.66 × 10− 6 LOC285626
Odds ratios (OR) calculated with respect to the minor allele. P values are adjusted for age, duration of diabetes, sex, hypertension, nephropathy (defined as microalbuminuria
or worse), HbA1c and the first 3 principal components. Chr chromosome, MAF minor allele frequency
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nearest protein coding gene is IL12B (Interleukin 12B), a
further 33 kb upstream. IL12B is expressed in the retina
(The Ocular Tissue Database [20]) and has been impli-
cated in both type 1 [23, 24] and type 2 diabetes [25], al-
though there are no prior reports of a role in diabetic
eye disease. NRXN3 (Neurexin 3) is located approxi-
mately 90 kb upstream from the three associated SNPs
on chromosome 14 and is strongly expressed in the ret-
ina. The gene encodes multiple transcripts and although
the exact function of each is unknown, neurexin proteins
function as cell adhesion molecules and receptors in
neurons. Genetic variants in NRXN3 have been associ-
ated with increased waist circumference and obesity [26,
27], which are important risk factors for and features of
type 2 diabetes [28, 29] and central obesity is a risk
factor for DR [30, 31]. NRXN3 polymorphisms are also as-
sociated with smoking behaviour [32], which in turn is a
risk factor for age-related macular degeneration [33] al-
though the contributory role of smoking to DR is less than
for age-related macular degeneration. If NRXN3 is con-
firmed to be important in PDR, there may be overlapping
genetic risk factors for risk of type 2 diabetes and PDR.
None of the highest ranked SNPs in this study have pre-
viously been reported in other GWAS of DR [10–12, 14,
34]. All but one of these studies [14] were of non-
Caucasian participants. If there is a genetic component to
susceptibility which is linked with ethnicity, it could ex-
plain the difficulty in replicating results from these other
studies. The lack of support for SNPs found in this current
study with other published GWAS does not discount their
possible association with DR. Replication analyses with
larger numbers of participants would provide greater stat-
istical power to confirm their association with PDR and/
or DME. Similarly, molecular manipulation of cultured
cell and animal models may be informative.
We have also directly compared the results of our
DME and PDR GWAS to the only other DR GWAS of
Caucasians [14]. Grassi et al. [14] reported a GWAS of
severe DR in type 1 diabetes in Caucasian Americans,
defined as PDR or DME. Similar to the current study,
no variants were reported at the genome-wide significant
level, however, several loci showed suggestive association
(p < 1 × 10− 5). One of the top ranked variants,
rs12267418, trended towards association with severe DR
in the earlier report (p = 8.2 × 10− 6) [14] and with DME
in the current study (p = 0.008, 8 loci tested). This SNP
is located within an intron of the MALRD1 gene on
chromosome 10. Very little is known about the function
of MALRD1 (MAM and LDL receptor class A domain
containing 1). Another recent study [35] on DR in a
Chinese type 2 diabetic population included two SNPs
within the MALRD1 gene, although an association was not
found (rs17670074 p = 0.27, rs9888035 p = 0.30). Further
research is needed to understand the possible role of this
gene in DR and whether ethnic differences or epigenetic
effects might be responsible for the differing results.
We also show nominal association at the chromosome
20 locus near PCSK2 reported by Grassi et al. Due to
the use of different SNP arrays in the two studies, we re-
port results for rs16999051 whereas the earlier report
Table 4 Comparison of GWAS findings for DME and PDR with a previously published GWAS for sight-threatening DR in a Caucasian
population (Grassi et al., 2011 [14])
p < 0.006 was required for significance to account for the eight loci tested (as separated by horizontal bold lines). Nominally significant p-values (p < 0.05) are
shown in bold. Proxy SNPs were used in this study when published SNPs were not available. Proxy SNPs were selected based on r2 value with the reported SNP in
the CEU population of HapMap. 95% CI for the OR was not reported by Grassi et al., 2011 [14])
aIn Grassi et al. 2011, the MALRD1 locus was labelled as C10orf112 and NPIPB8 was labelled as CCDC101b and SULT1Ac
dSNP with lowest p-value within 50 kb of the published SNP (no appropriate proxy SNP identified)
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was for rs737141. The association of this SNP with PDR
was very close to significance (p = 0.007) and the SNP also
reached nominal significance with DME (p = 0.038). This
may suggest some overlap in the genetic susceptibility to
different diabetic ocular complications, but may also be
due to the number of DME patients who also have PDR.
This SNP is located within an intron of the PCSK2 gene
on chromosome 20. The proprotein convertase subtilisin/
kexin-type 2 gene has been well-documented in its link to
susceptibility to type 2 diabetes [36, 37].
This study compared type 2 diabetes participants with
type 1 diabetic participants in Grassi et al. (2011) [14].
The similar trends at several SNPs may suggest that
some loci are associated with DR regardless of diabetes
type. Similarly, the DR associated SNP found in our ori-
ginal report [13], rs9896052, was found in the discovery
type 2 diabetes cohort as well as the replication type 1
diabetes group, again suggesting that at least some DR
risk factors are common between types of diabetes.
A strength of this study is the size of the original co-
hort relative to other DR studies [15], and the detailed
clinical evaluation of the participants. Stratifying the
sight-threatening phenotype of our earlier study [13]
into DME and PDR provided more homogeneous groups
for analysis. This study is comparable in size to other
published GWAS for DR phenotypes and provides a use-
ful breakdown of data from the previously reported
composite phenotype of blinding retinopathy [13], al-
though we have a limited ability to detect small effect
sizes. A recognised limitation is that 93 participants have
both PDR and DME, indicating that these phenotypes
may not be independent even though we have con-
ducted the analyses separately. This issue will affect any
cohort of diabetic patients and can only be unravelled
using larger cohorts and laboratory based functional
testing. It is noteworthy that many participants have
either DME or PDR, supporting the hypothesis that
different factors lead to these different clinical pheno-
types. Further value could be gained from the data by a
meta-analysis with other reported studies, following
harmonization of phenotypes. Imputation of un-
genotyped SNPs may also reveal additional loci, however,
most loci detected through imputation are also tagged
by directly genotyped SNPs. Such analyses are likely to
be of limited value in this small cohort. Replication co-
horts are also required to fully evaluate the findings re-
ported herein, particularly as genome-wide statistical
significance was not reached. Relevant basic science
studies are also merited.
Conclusions
This is the first GWAS specifically targeting DME and
PDR separately as ocular complications of sight-
threatening DR. MRPL19 and NRXN3 have been
identified as novel loci with suggestive association with
DME and PDR respectively. Two long non-coding RNAs
of unknown function (LINC00343 and LOC285626) have
also been highlighted as possible candidates for these
common, blinding complications of diabetes, however,
further genetic studies are warranted to confirm these
findings. This study has also provided supportive evi-
dence for previously reported loci, PCKS2 and MALRD1
in DR in Caucasians. Despite recent advances in treat-
ment for diabetes related systemic risk factors and of
local DME and PDR with anti-VEGF therapies and feno-
fibrate [38], many patients remain visually impaired.
Studies such as this can lead to clearer understanding of
important biological pathways relevant to disease and
will be important tools in the global fight to prevent
blindness from diabetes.
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